Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.5% – What’s Next?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANAGet Free Report) were down 5.5% on Wednesday . The company traded as low as $3.32 and last traded at $3.43. Approximately 2,229,711 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 27,671,803 shares. The stock had previously closed at $3.63.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SANA shares. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright lifted their target price on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.25.

View Our Latest Research Report on SANA

Sana Biotechnology Price Performance

The stock has a market cap of $725.63 million, a P/E ratio of -2.32 and a beta of 1.45. The company has a fifty day moving average price of $2.42 and a 200 day moving average price of $4.01.

Sana Biotechnology (NASDAQ:SANAGet Free Report) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, sell-side analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its holdings in Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after buying an additional 178,179 shares in the last quarter. FMR LLC grew its holdings in Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after buying an additional 4,438,949 shares in the last quarter. Geode Capital Management LLC grew its holdings in Sana Biotechnology by 9.6% during the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after buying an additional 276,055 shares in the last quarter. Stifel Financial Corp purchased a new position in Sana Biotechnology in the third quarter worth $43,000. Finally, Integral Health Asset Management LLC boosted its position in Sana Biotechnology by 22.4% in the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after purchasing an additional 220,000 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Read More

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.